Roche hands Chinese biotech $70M for HER2 drug that can go to the brain
Roche is still hunting for next-generation drugs that can hit HER2-positive cancer, and it’s found a Phase I candidate it likes from a Chinese biotech.
The Swiss pharma giant will pay Zion Pharma $70 million in upfront and near-term milestones to get its hands on an oral HER2 tyrosine kinase inhibitor.
HER2, or the human epidermal growth factor receptor 2, is an increasingly popular target for cancer drugmakers, with AstraZeneca, Seagen and many other biotechs betting on new molecules.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters